UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016

Journal of thoracic oncology, 2016-07, Vol.11 (7), p.946-963

2016

Volltextzugriff (PDF)

Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC

Journal of thoracic oncology, 2020-03, Vol.15 (3), p.324-343

2020

Volltextzugriff (PDF)

The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung

Journal of thoracic oncology, 2019-07, Vol.14 (7), p.1213-1222

2019

Volltextzugriff (PDF)

Is the LENT Score Already Outdated?

Respiration, 2018-01, Vol.96 (4), p.303-304

2018

Volltextzugriff (PDF)

Targeting Epidermal Growth Factor Receptor in the Management of Lung Cancer

Seminars in oncology, 2014-02, Vol.41 (1), p.101-109

2014

Volltextzugriff (PDF)

Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor

Journal of thoracic oncology, 2015-09, Vol.10 (9), p.1292-1300

2015

Volltextzugriff (PDF)

Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS)

Lung cancer (Amsterdam, Netherlands), 2014-02, Vol.83 (2), p.174-181

2014

Volltextzugriff (PDF)

Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography

Journal of clinical oncology, 2016-01, Vol.34 (1), p.91-101

2016

Volltextzugriff (PDF)

Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade

Cancer research (Chicago, Ill.), 2018-11, Vol.78 (22), p.6486-6496

2018

Volltextzugriff (PDF)

Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions

Lung cancer (Amsterdam, Netherlands), 2018-01, Vol.115, p.12-20

2018

Volltextzugriff (PDF)

Personalized medicine in lung cancer: what we need to know

Nature reviews. Clinical oncology, 2011-11, Vol.8 (11), p.661-668

Mok, Tony S. K

2011

Volltextzugriff (PDF)

Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations

Journal of clinical oncology, 2013-09, Vol.31 (27), p.3342-3350

2013

Volltextzugriff (PDF)

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Journal of clinical oncology, 2011-07, Vol.29 (21), p.2866-2875

2011

Volltextzugriff (PDF)

Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin

Genome research, 2019-03, Vol.29 (3), p.418-427

2019

Volltextzugriff (PDF)

Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non - Small Cell Lung Cancer Patients

Clinical cancer research, 2009-03, Vol.15 (6), p.2076-2084

2009

Volltextzugriff (PDF)

Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab

Journal of clinical oncology, 2009-02, Vol.27 (4), p.605-611

2009

Volltextzugriff (PDF)

ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI

Lung cancer (Amsterdam, Netherlands), 2020-04, Vol.142, p.41-46

2020

Volltextzugriff (PDF)

Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2009-10, Vol.27 (30), p.5080-5087

2009

Volltextzugriff (PDF)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC

Lung cancer (Amsterdam, Netherlands), 2017-02, Vol.104, p.119-125

2017

Volltextzugriff (PDF)

New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy

Journal of clinical oncology, 2009-01, Vol.27 (3), p.446-452

2009

Volltextzugriff (PDF)

Novel method for rapid identification of micropapillary or solid components in early-stage lung adenocarcinoma

The Journal of thoracic and cardiovascular surgery, 2018-12, Vol.156 (6), p.2310-2318.e2

2018

Volltextzugriff (PDF)

A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma

Investigational new drugs, 2021-10, Vol.39 (5), p.1375-1382

2021

Volltextzugriff (PDF)

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

JTO clinical and research reports, 2021-08, Vol.2 (8), p.100205-100205, Article 100205

2021

Volltextzugriff (PDF)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study

Lung cancer (Amsterdam, Netherlands), 2013-08, Vol.81 (2), p.280-287

2013

Volltextzugriff (PDF)

The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy

Cancer treatment reviews, 2017-04, Vol.55, p.181-189

2017

Volltextzugriff (PDF)

1 – 25 von 169

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(161)
Mit Volltextzugriff
(153)

Publikationsform

Artikel
(169)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(153)
Life Sciences & Biomedicine
(151)
Humans
(130)
Oncology
(111)
Female
(72)
Male
(69)
Middle Aged
(63)
Aged
(55)
Adult
(50)
Lung Neoplasms - Drug Therapy
(45)
Biological And Medical Sciences
(41)
Lung Cancer
(41)
Medical Sciences
(40)
Lung Neoplasms - Pathology
(39)
Respiratory System
(39)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(37)
Tumors
(36)
Lung Neoplasms - Genetics
(32)
Mutation
(32)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(29)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016

Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC

The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung

Is the LENT Score Already Outdated?

Targeting Epidermal Growth Factor Receptor in the Management of Lung Cancer

Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor

Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS)

Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography

Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade

Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions

Personalized medicine in lung cancer: what we need to know

Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin

Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non - Small Cell Lung Cancer Patients

Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab

ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI

Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC

New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy

Novel method for rapid identification of micropapillary or solid components in early-stage lung adenocarcinoma

A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study

The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy

Suchergebnisse filtern